Polymeric nanoparticles for sustained down-regulation of annexin A2 inhibit prostate tumor growth

Arthur R. Braden, Michael T. Kafka, Linda Cunningham, Harlan Jones, Jamboor K. Vishwanatha

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer related death in Western men. In prostate intraepithelial neoplasia annexin A2 expression is absent however upon loss of androgen dependence annexin A2 is subsequently over-expressed. Regaining regulatory control of annexin A2 presents a means of therapy in the treatment of hormone refractory prostate cancers. In an effort to regain control of aberrant annexin A2 expression we have formulated poly lactide-co-glycolide (PLGA) nanoparticles loaded with pDrive-sh AnxA2 plas-mid DNA. These nanoparticles are capable of sustained intracellular delivery of pDrive-sh AnxA2 plasmid DNA vector for long term siRNA mediated down-regulation of annexin A2. Intra-tumorai administration of pDrive-sh AnxA2 loaded nanoparticles to xenograft prostate tumors in nude mice demonstrates an overall decrease in tumor growth. The decrease in tumor growth is through a reduction of annexin A2 and VEGF mRNA and protein levels within the tumor mass. Administration of blank nanoparticles demonstrated no alteration in tumor growth or annexin A2 and VEGF at either the mRNA or protein levels. Our findings suggest that the use of sustained-release polymeric nanoparticles for down-regulation of annexin A2 expression may serve as an effective adjuvant treatment option for prostate cancer.

Original languageEnglish
Pages (from-to)2856-2865
Number of pages10
JournalJournal of Nanoscience and Nanotechnology
Volume9
Issue number5
DOIs
StatePublished - 1 May 2009

Fingerprint

Annexin A2
Nanoparticles
Tumors
Prostate
tumors
Down-Regulation
cancer
nanoparticles
Growth
Neoplasms
DNA
Prostatic Neoplasms
deoxyribonucleic acid
proteins
Proteins
Regain
plasmids
hormones
Vascular Endothelial Growth Factor A
Hormones

Keywords

  • Annexin A2
  • Nanoparticle
  • PLGA
  • Prostate
  • Sirna.

Cite this

@article{fb781d5eed604839ad42266de651ef5e,
title = "Polymeric nanoparticles for sustained down-regulation of annexin A2 inhibit prostate tumor growth",
abstract = "Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer related death in Western men. In prostate intraepithelial neoplasia annexin A2 expression is absent however upon loss of androgen dependence annexin A2 is subsequently over-expressed. Regaining regulatory control of annexin A2 presents a means of therapy in the treatment of hormone refractory prostate cancers. In an effort to regain control of aberrant annexin A2 expression we have formulated poly lactide-co-glycolide (PLGA) nanoparticles loaded with pDrive-sh AnxA2 plas-mid DNA. These nanoparticles are capable of sustained intracellular delivery of pDrive-sh AnxA2 plasmid DNA vector for long term siRNA mediated down-regulation of annexin A2. Intra-tumorai administration of pDrive-sh AnxA2 loaded nanoparticles to xenograft prostate tumors in nude mice demonstrates an overall decrease in tumor growth. The decrease in tumor growth is through a reduction of annexin A2 and VEGF mRNA and protein levels within the tumor mass. Administration of blank nanoparticles demonstrated no alteration in tumor growth or annexin A2 and VEGF at either the mRNA or protein levels. Our findings suggest that the use of sustained-release polymeric nanoparticles for down-regulation of annexin A2 expression may serve as an effective adjuvant treatment option for prostate cancer.",
keywords = "Annexin A2, Nanoparticle, PLGA, Prostate, Sirna.",
author = "Braden, {Arthur R.} and Kafka, {Michael T.} and Linda Cunningham and Harlan Jones and Vishwanatha, {Jamboor K.}",
year = "2009",
month = "5",
day = "1",
doi = "10.1166/jnn.2009.028",
language = "English",
volume = "9",
pages = "2856--2865",
journal = "Journal of Nanoscience and Nanotechnology",
issn = "1533-4880",
publisher = "American Scientific Publishers",
number = "5",

}

Polymeric nanoparticles for sustained down-regulation of annexin A2 inhibit prostate tumor growth. / Braden, Arthur R.; Kafka, Michael T.; Cunningham, Linda; Jones, Harlan; Vishwanatha, Jamboor K.

In: Journal of Nanoscience and Nanotechnology, Vol. 9, No. 5, 01.05.2009, p. 2856-2865.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Polymeric nanoparticles for sustained down-regulation of annexin A2 inhibit prostate tumor growth

AU - Braden, Arthur R.

AU - Kafka, Michael T.

AU - Cunningham, Linda

AU - Jones, Harlan

AU - Vishwanatha, Jamboor K.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer related death in Western men. In prostate intraepithelial neoplasia annexin A2 expression is absent however upon loss of androgen dependence annexin A2 is subsequently over-expressed. Regaining regulatory control of annexin A2 presents a means of therapy in the treatment of hormone refractory prostate cancers. In an effort to regain control of aberrant annexin A2 expression we have formulated poly lactide-co-glycolide (PLGA) nanoparticles loaded with pDrive-sh AnxA2 plas-mid DNA. These nanoparticles are capable of sustained intracellular delivery of pDrive-sh AnxA2 plasmid DNA vector for long term siRNA mediated down-regulation of annexin A2. Intra-tumorai administration of pDrive-sh AnxA2 loaded nanoparticles to xenograft prostate tumors in nude mice demonstrates an overall decrease in tumor growth. The decrease in tumor growth is through a reduction of annexin A2 and VEGF mRNA and protein levels within the tumor mass. Administration of blank nanoparticles demonstrated no alteration in tumor growth or annexin A2 and VEGF at either the mRNA or protein levels. Our findings suggest that the use of sustained-release polymeric nanoparticles for down-regulation of annexin A2 expression may serve as an effective adjuvant treatment option for prostate cancer.

AB - Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer related death in Western men. In prostate intraepithelial neoplasia annexin A2 expression is absent however upon loss of androgen dependence annexin A2 is subsequently over-expressed. Regaining regulatory control of annexin A2 presents a means of therapy in the treatment of hormone refractory prostate cancers. In an effort to regain control of aberrant annexin A2 expression we have formulated poly lactide-co-glycolide (PLGA) nanoparticles loaded with pDrive-sh AnxA2 plas-mid DNA. These nanoparticles are capable of sustained intracellular delivery of pDrive-sh AnxA2 plasmid DNA vector for long term siRNA mediated down-regulation of annexin A2. Intra-tumorai administration of pDrive-sh AnxA2 loaded nanoparticles to xenograft prostate tumors in nude mice demonstrates an overall decrease in tumor growth. The decrease in tumor growth is through a reduction of annexin A2 and VEGF mRNA and protein levels within the tumor mass. Administration of blank nanoparticles demonstrated no alteration in tumor growth or annexin A2 and VEGF at either the mRNA or protein levels. Our findings suggest that the use of sustained-release polymeric nanoparticles for down-regulation of annexin A2 expression may serve as an effective adjuvant treatment option for prostate cancer.

KW - Annexin A2

KW - Nanoparticle

KW - PLGA

KW - Prostate

KW - Sirna.

UR - http://www.scopus.com/inward/record.url?scp=67549130802&partnerID=8YFLogxK

U2 - 10.1166/jnn.2009.028

DO - 10.1166/jnn.2009.028

M3 - Article

C2 - 19452941

AN - SCOPUS:67549130802

VL - 9

SP - 2856

EP - 2865

JO - Journal of Nanoscience and Nanotechnology

JF - Journal of Nanoscience and Nanotechnology

SN - 1533-4880

IS - 5

ER -